Yahui Long and executives fined a total of 7.5 million yuan for information disclosure violations, and may also face claims from injured shareholders.

Ask AI · What is the relationship between the performance decline of YHLO and information disclosure issues?

Radar Finance Written by: Yang Yang Edited by: Li Yihui

On March 17, YHLO (688575) announced that the company was administratively punished by the China Securities Regulatory Commission for violations of information disclosure laws and regulations. The information regarding the strategic cooperation with Shenzhen Brain-Computer Star Link Technology Co., Ltd. in the company’s “First Announcement” issued on January 6, 2026, was found to be inaccurate and incomplete. Subsequent “Supplementary Announcements” and “Inquiry Response Announcements” also did not fully disclose the actual development stage of related products and order status. These actions violated relevant provisions of the Securities Law, constituting misleading statement violations.

The company was ordered to rectify, given a warning, and fined 4 million yuan; Chairman Hu Kunhui and Board Secretary Wang Mingyang were each warned and fined 2 million yuan and 1.5 million yuan, respectively.

The company stated that this punishment did not involve circumstances that would mandate a forced delisting due to significant illegal activities, and that current business activities are operating normally.

It is noteworthy that YHLO may also face claims due to information disclosure issues.

In this regard, Song Lianmin, the head of Jiangsu Shengheng Law Firm, which has represented numerous stock claims and settlements, told Radar Finance that if a listed company’s information disclosure is untimely or inaccurate, causing losses to investors, affected investors can claim compensation according to the law. Any investor who purchased YHLO stock between the listing and February 6, 2026, and held it at the close on February 7, 2026, can register for compensation. For registration, please follow the public account “Leizhubar” (Leizhu Code: 99) to participate, with no costs incurred before compensation.

According to Tianyancha data, YHLO was established on September 17, 2008, with a registered capital of 571.3883 million yuan. The legal representative is Song Yongbo, and the registered address is Building 1, YHLO Biotech Plant, Baolong Second Road, Baolong Street, Longgang District, Shenzhen. The main business is the research, development, production, and sales of in vitro diagnostic instruments and supporting reagents primarily based on chemiluminescence immunoassay methods, as well as the agency sales of some non-self-produced medical device products.

Currently, the chairman of the company is Hu Kunhui, the board secretary is Wang Mingyang, and the number of employees is 1,753. The actual controller is Hu Kunhui.

The company has stakes in 23 subsidiaries, including Changsha YHLO Biotech Co., Ltd., Wuhan Dexin Bio Technology Co., Ltd., Shanghai YHLO Medical Technology Co., Ltd., Shenzhen Kaiyuan Medical Devices Co., Ltd., and Shenzhen Ruipu Jia Trade Co., Ltd.

In terms of performance, the company’s operating revenues for 2022, 2023, and 2024 were 3.981 billion yuan, 2.053 billion yuan, and 2.012 billion yuan, with year-on-year growth rates of 237.95%, -48.42%, and -2.02%, respectively. The net profit attributable to the parent company was 1.012 billion yuan, 355 million yuan, and 302 million yuan, with year-on-year growth rates of 394.46%, -64.92%, and -15.06%, respectively. During the same period, the company’s debt-to-asset ratios were 41.95%, 33.43%, and 38.81%.

In terms of risk, Tianyancha information shows that the company has 65 internal Tianyan risks, 86 surrounding Tianyan risks, 10 historical Tianyan risks, and 253 warning alerts regarding Tianyan risks.